drugset / Trial / NCT01530711

Treatment of Hepatorenal Syndrome With Terlipressin Infusion Adjusted to Hemodynamic Response

NCT01530711

Phase 4 Unknown 40 enrolled Pere Gines
NaSingle-groupOpen-labelTreatment

Summary

Observe the effect of terlipressin on renal function in patients with SHR type I adjusting the dose based on hemodynamic response.

Timeline

Start
2012-04
Primary completion
2016-12
Completion
2016-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Terlipressin Peptide 2 mg
Background Albumin Protein / enzyme biologic 20 g
Background Albumin Protein / enzyme biologic 40 g